Original Article
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
N Engl J Med 2010; 363:221-232July 15, 2010
- Abstract
Background
Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)−associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen.
Methods
We conducted a multicenter, randomized, double-blind, double-dummy, noninferiority trial of rituximab (375 mg per square meter of body-surface area per week for 4 weeks) as compared with cyclophosphamide (2 mg per kilogram of body weight per day) for remission induction. Glucocorticoids were tapered off; the primary end point was remission of disease without the use of prednisone at 6 months.
Results
Nine centers enrolled 197 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis. Baseline disease activity, organ involvement, and the proportion of patients with relapsing disease were similar in the two treatment groups. Sixty-three patients in the rituximab group (64%) reached the primary end point, as compared with 52 patients in the control group (53%), a result that met the criterion for noninferiority (P<0.001). The rituximab-based regimen was more efficacious than the cyclophosphamide-based regimen for inducing remission of relapsing disease; 34 of 51 patients in the rituximab group (67%) as compared with 21 of 50 patients in the control group (42%) reached the primary end point (P=0.01). Rituximab was also as effective as cyclophosphamide in the treatment of patients with major renal disease or alveolar hemorrhage. There were no significant differences between the treatment groups with respect to rates of adverse events.
Conclusions
Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)
Media in This Article
Figure 1
Randomization and Inclusion in the Analysis at 6 Months.Figure 2
Treatment Effect According to Prednisone Dose at 6 Months.Article Activity
- Article
Wegener's granulomatosis and microscopic polyangiitis are classified as antineutrophil cytoplasmic antibody (ANCA)−associated vasculitides because most patients with generalized disease have antibodies against proteinase 3 or myeloperoxidase.1,2 The ANCA-associated vasculitides affect small-to-medium-size blood vessels, with a predilection for the respiratory tract and kidneys.3-6
Cyclophosphamide and glucocorticoids have been the standard therapy for remission induction for nearly four decades.7,8 This regimen transformed the usual treatment outcome of severe ANCA-associated vasculitis from death to a strong likelihood of disease control and temporary remission.3-5,9-11 However, not all patients have a remission with this combination of drugs, and those who do often have disease flares that require repeated treatment. Moreover, side effects of cyclophosphamide, including infertility, cytopenias, infections, bladder injury, and cancer, as well as the multiple adverse effects of lengthy courses of glucocorticoid treatment, are major causes of long-term disease and death.3-5,10-14
B lymphocytes play an important role in the pathogenesis of autoimmune diseases, including ANCA-associated vasculitis.15 In ANCA-associated vasculitis, the percentage of activated peripheral-blood B lymphocytes correlates with disease activity, and certain effects of cyclophosphamide on B lymphocytes are associated with treatment efficacy.16-19 Rituximab, an anti-CD20 monoclonal antibody, depletes B lymphocytes through a variety of mechanisms. In uncontrolled studies, rituximab has shown promise as a remission-induction agent in ANCA-associated vasculitis.20-23
We conducted the Rituximab in ANCA-Associated Vasculitis (RAVE) trial, a multicenter, randomized, double-blind, double-dummy, noninferiority trial to compare rituximab with standard cytotoxic therapy for the induction of complete remission by 6 months in patients with severe ANCA-associated vasculitis. We hypothesized that treatment with rituximab plus glucocorticoids would not be inferior to daily cyclophosphamide plus glucocorticoids for remission induction and would permit discontinuation of prednisone by 6 months. A related article on a randomized trial of rituximab versus cyclophosphamide in ANCA-associated vasculitis (RITUXVAS; Current Controlled Trials number, ISRCTN28528813) to assess the treatment response and rates of severe adverse events with a rituximab-based regimen appears elsewhere in this issue of the Journal.24
Methods
Study Design and Patients
The first and last authors designed the trial in collaboration with the clinical development team at the Immune Tolerance Network and clinical investigators of the RAVE research group. The site investigators gathered the data, and the data were analyzed by the RAVE data committee, which consisted of the two coprincipal investigators and representatives of the Immune Tolerance Network, the National Institute of Allergy and Infectious Diseases, and the coordinating center (Rho). The data committee did not include representatives of either Genentech or Biogen Idec, which provided funding and medications for the study. The manuscript was drafted and written by the first and last authors, with input as appropriate from members of the RAVE data committee and the clinical investigators. The RAVE data committee made the decision to submit the manuscript for publication, and the first and last authors vouch for the accuracy and completeness of the data and analyses.
Both the full study-entry criteria, included in the Supplementary Appendix, and the trial protocol are available with the full text of this article at NEJM.org. Briefly, patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had positive serum assays for proteinase 3–ANCA or myeloperoxidase-ANCA, manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease).25 Patients with either newly diagnosed or relapsing disease were eligible for enrollment. The RAVE trial was approved by the institutional review board at each participating site. All patients provided written informed consent.
Patients were randomly assigned, in a 1:1 ratio, to investigational therapy (the rituximab group) or standard therapy (the control group). Randomization was stratified according to clinical site and ANCA type.
Treatments
The remission-induction period was 6 months. The rituximab group received intravenous rituximab (Rituxan, Genentech) (at a dose of 375 mg per square meter of body-surface area once weekly for 4 weeks) plus daily placebo−cyclophosphamide. The control group received placebo−rituximab infusions plus daily cyclophosphamide (2 mg per kilogram of body weight, adjusted for renal insufficiency). Patients in the control group who had a remission between 3 and 6 months were eligible to switch from cyclophosphamide to azathioprine (2 mg per kilogram per day).10 Patients in the rituximab group with a remission during the same 3-to-6-month period were switched from placebo−cyclophosphamide to placebo−azathioprine.
The two treatment groups received the same glucocorticoid regimen: one to three pulses of methylprednisolone (1000 mg each), followed by prednisone at a dose of 1 mg per kilogram per day. The dose was tapered so that by 5 months, all patients who had a remission without disease flares had discontinued glucocorticoids (see the Supplementary Appendix).
Assessments
Study visits occurred at baseline; at weeks 1, 2, 3, and 4; and at 2, 4, and 6 months. Disease activity was measured on the basis of the BVAS/WG and the physician's global assessment.25 Damage related to disease or treatment was scored according to the Vasculitis Damage Index (scores for this index range from 0 to 64, with higher scores indicating more severe damage).26 Health-related quality of life was scored with the use of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36).27 Scores on this scale range from 0 to 100, with higher scores indicating better health.
Serial serum samples were tested for proteinase 3–ANCA and myeloperoxidase-ANCA by means of a direct enzyme-linked immunosorbent assay (ELISA).28
End Points
The primary end point was a BVAS/WG of 0 and successful completion of the prednisone taper at 6 months. Secondary end points included rates of disease flares, a BVAS/WG of 0 during treatment with prednisone at a dose of less than 10 mg per day, cumulative glucocorticoid doses, rates of adverse events, and SF-36 scores. A disease flare was defined as an increase in the BVAS/WG of 1 point or more. Patients who had severe flares during the first 6 months were eligible for crossover to the other treatment group in a blinded fashion. Those who crossed over received the other induction regimen in full. Limited flares were treated by increasing the dose of prednisone.
Patients were classified as having early treatment failure if at 1 month their BVAS/WG had not decreased by at least 1 point or a new manifestation of disease had emerged. Patients with early treatment failure discontinued their assigned treatments, received therapies according to best medical judgment, and were counted as having failure with respect to the primary end point.
Adverse Events
All adverse events were graded according to the National Cancer Institute's Common Terminology Criteria.29 During protocol development, the study team and the Food and Drug Administration identified nine major adverse events, termed selected adverse events, for priority analysis. These events included deaths (from all causes), malignant conditions, grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, drug-induced cystitis, venous thromboembolic events, stroke, hospitalizations, and infusion reactions that contraindicated further infusions.
Statistical Analysis
In calculating the sample size, we assumed that 70% of the patients in both treatment groups would have disease remission after the discontinuation of prednisone at 6 months. We specified a noninferiority margin of −20 percentage points for the difference in remission rates (the rate in the rituximab group minus the rate in the control group) and a one-sided alpha level of 0.025. Assuming a 10% dropout rate, we calculated that we would need to enroll 100 patients in each group for an 83% statistical power to demonstrate noninferiority.
Primary analyses were performed by the intention-to-treat method. Patients who dropped out of the study before 6 months were considered to have a treatment failure with respect to the primary end point. We assessed noninferiority by comparing the lower limit of the 95.1% confidence interval for the mean treatment difference (the rate in the rituximab group minus the rate in the control group) to −20 percentage points and testing the corresponding hypothesis that the difference would be greater than −20 percentage points. Superiority was assessed by means of a one-tailed t-test comparing the mean treatment difference with zero. To assess the consistency of the study results, analyses were repeated for predefined subgroups based on the following baseline variables: type of ANCA-associated vasculitis, type of ANCA, newly diagnosed disease, relapsing disease, alveolar hemorrhage, and severe renal disease. With analysis of eight subgroups, chance alone would result in 0.39 statistically significant results (P<0.05). We did not correct these subgroup analyses for multiplicity because they were prespecified and had biologically plausible bases.
For other analyses, two-sample comparisons were performed with the use of Student's t-test or a Wilcoxon rank-sum test for continuous measures and a chi-square test or Fisher's exact test for binary measures. Adjusted analyses were performed by means of analysis of covariance or logistic regression. Baseline covariates for these analyses included type of ANCA, new versus relapsing disease, renal function, and BVAS/WG. Rates of adverse events were compared with the use of Poisson regression. All statistical tests were two-sided, and a P value of less than 0.05 was considered to indicate statistical significance (see the Supplementary Appendix for details of the interim analysis).
Results
Patients
Between December 30, 2004, and June 30, 2008, a total of 197 patients with ANCA-associated vasculitis were enrolled at nine clinical sites participating in the study (Figure 1Figure 1
Randomization and Inclusion in the Analysis at 6 Months.). The baseline characteristics of the patients are listed in Table 1Table 1
Baseline Demographic and Clinical Characteristics of the Patients.. Ninety-nine patients were assigned to the rituximab group, and 98 patients were assigned to the control group. The treatment groups were balanced with respect to Wegener's granulomatosis versus microscopic polyangiitis, patients with newly diagnosed disease, disease activity, organ involvement, pre-enrollment therapy, past exposure to cyclophosphamide, and total glucocorticoids administered in the interval from 14 days before informed consent was obtained to the first investigational infusion (Table 1). Forty-eight patients (24%) had diagnoses of microscopic polyangiitis, and 148 (75%) had diagnoses of Wegener's granulomatosis. The specific diagnosis was indeterminate in 1 patient. Approximately 49% of patients in both groups had a new diagnosis. The mean (±SD) BVAS/WG scores at entry were 8.5±3.2 in the rituximab group and 8.2±3.2 in the control group.Ninety-seven percent of all patients received at least three study-drug infusions. None were lost to follow-up. Eighty-four of the patients who were randomly assigned to the rituximab group (85%) and 81 of those who were randomly assigned to the control group (83%) completed 6 months of treatment without meeting criteria for early treatment failure, crossing over to the other treatment group, switching to a therapy based on best medical judgment, or withdrawing from the protocol for other reasons (Figure 1).
Efficacy Assessments
End Points
Sixty-three of the 99 patients in the rituximab group (64%) reached the primary end point, as compared with 52 of 98 in the control group (53%). The treatment difference of 11 percentage points between the groups met the criterion for noninferiority (P<0.001). The proportion of patients who reached the primary end point was larger in the rituximab group than in the control group, but the difference was not significant (95.1% confidence interval [CI], −3.2 to 24.3 percentage points; P=0.09) (Figure 2Figure 2
Treatment Effect According to Prednisone Dose at 6 Months.). Seventy patients treated with rituximab (71%) reached the secondary end point of disease remission while receiving less than 10 mg per day of prednisone, as compared with 61 patients in the control group (62%, P=0.10).ANCA type, newly diagnosed disease, renal function, BVAS/WG, and age did not affect the primary comparison when examined in logistic-regression models (data not shown). However, among patients with relapsing disease at baseline, rituximab was more efficacious than cyclophosphamide: 34 of 51 patients in the rituximab group (67%) reached the primary end point, as compared with only 21 of 50 in the control group (42%, P=0.01). Evidence of the superior efficacy of rituximab among patients with relapsing disease at baseline persisted even after adjustment for differences in ANCA type and clinical site (odds ratio, 1.40; 95% CI, 1.03 to 1.91; P=0.03).
Disease Type
Among patients with Wegener's granulomatosis, 46 of 73 assigned to rituximab (63%) and 37 of 74 treated with cyclophosphamide (50%) reached the primary end point (P=0.11). Among the patients with microscopic polyangiitis, 16 of 24 in the rituximab group (67%) and 15 of 24 in the control group (62%) reached the primary end point (P=0.76).
Major Renal Disease at Baseline
A subgroup of patients had at least one major renal BVAS/WG item at baseline (i.e., urinary red-cell casts, biopsy-confirmed glomerulonephritis, or an increase in the baseline serum creatinine concentration of more than 30%). Fifty-one of the patients in the rituximab group (52%) had at least one major renal item at baseline, as compared with 51 in the control group (52%). In this subgroup, baseline renal function in the rituximab group was worse than in the control group (mean [±SD] estimated creatinine clearance, 53.8±29.8 ml per minute vs. 68.9±41.6 ml per minute; P=0.04). However, the estimated creatinine clearances increased in parallel in the two groups during the first 6 months (by 11.2 ml per minute in the rituximab group and 10.5 ml per minute in the control group), and the percentages of patients who reached the primary end point were not significantly different (31 of 51 patients in the rituximab group [61%] vs. 32 of 51 patients in the control group [63%], P=0.92).
Alveolar Hemorrhage at Baseline
Twenty-eight patients in the rituximab group (28%) had alveolar hemorrhage at baseline, as compared with 27 in the control group (28%). Among these patients, 16 (57%) and 11 (41%), respectively, reached the primary end point (P=0.48).
Severity of Flares
Six patients in the rituximab group and 10 in the control group had severe disease flares. The rates of severe flares were 0.011 and 0.018 per patient-month, respectively (P=0.30). There was no significant between-group difference in the number of limited flares: there were 13 flares in 11 patients in the rituximab group and 15 flares in 14 patients in the control group. The rates of limited disease flares were 0.023 and 0.027 per patient-month, respectively (P=0.81).
Damage and Quality of Life
Scores on the Vasculitis Damage Index increased by 1.3 points from baseline to 6 months in the rituximab group and by 1.5 points in the control group (P=0.62). Quality-of-life outcomes did not differ significantly between the two groups (see the Supplementary Appendix).
Peripheral-Blood B-Lymphocyte Counts
The number of peripheral-blood CD19+ B cells decreased to less than 10 cells per cubic millimeter after two infusions of rituximab and remained at that level in most patients through 6 months (Figure 3Figure 3
Peripheral-Blood B-Cell Counts.). In the rituximab group, 87 of 93 patients (94%) had this degree of B-cell depletion at 1 month. Among the patients who did not have B-cell depletion, 4 patients reached the primary end point and 1 patient did not. In the control group, peripheral-blood CD19+ B-cell counts also decreased, but the rate and magnitude of the decrease were less than in the rituximab group.ANCA Response
Among patients who remained in their original treatment groups, 47% in the rituximab group and 24% in the control group became ANCA-negative by 6 months (P=0.004). This difference between the two treatment groups in loss of ANCA reactivity was due to changes in the subgroup of patients who were initially positive for proteinase 3−ANCA. Fifty percent of such patients in the rituximab group became negative for proteinase 3−ANCA, as compared with only 17% in the control group (P<0.001). In contrast, equivalent percentages of patients in the rituximab and control groups became negative for myeloperoxidase−ANCA (40% vs. 41%, P=0.95). The loss of ANCA reactivity, as measured by means of direct ELISA, was not significantly associated with attainment of the primary end point.
Adverse Events
There were no significant differences between the treatment groups in the numbers of total adverse events, serious adverse events, or non−disease-related adverse events, or in the number of participants with at least one non−disease-related adverse event (Table 2Table 2
Adverse Events at 6 Months.). Fourteen patients in the rituximab group (14%) and 17 in the control group (17%) had events leading to discontinuation of treatment.More patients in the control group than in the rituximab group had one or more of the predefined selected adverse events: 32 (33%) versus 22 (22%) (P=0.01) (Table 2). More episodes of grade 2 or higher leukopenia (white-cell count, <3000 per cubic millimeter) in the control group (10, vs. 3 in the control group) accounted for most of this difference (Table 2). Eight patients in the rituximab group were hospitalized for adverse events related to either the disease or its treatment, as compared with 2 in the control group. No pattern emerged with respect to causes of hospitalization. During the first 6 months of the trial, solid malignant tumors were diagnosed in 1 patient in each group; 2 patients in the control group and 1 in the rituximab group died.
Six malignant conditions developed in 5 additional patients after 6 months. Four of those patients had been assigned initially to rituximab and one had been assigned to cyclophosphamide. The specific types of solid malignant tumors among patients who received rituximab were papillary thyroid cancer (in 1 patient), uterine cancer (in 1 patient), prostate cancer (in 1 patient), colon cancer (in 2 patients), bladder cancer (in 1 patient), and lung cancer (in 1 patient). The specific types of solid malignant tumors among patients who received cyclophosphamide were prostate cancer (in 1 patient) and lung cancer (in 1 patient). Among patients with exposure to rituximab during the trial, malignant conditions developed in 6 of 124 (5%), as compared with 1 of 73 patients without exposure to rituximab (1%, P=0.26). With the exception of two cases of prostate cancer, all patients in whom malignant conditions developed had histories of exposure to at least two medications known to increase the risk of cancer (cyclophosphamide, azathioprine, or methotrexate) (see the Supplementary Appendix).
Discussion
Although a randomized, controlled trial involving patients with severe ANCA-associated vasculitis that compared cyclophosphamide head to head with another agent had long been deemed unethical,30 uncontrolled studies have suggested that rituximab has efficacy for remission induction in ANCA-associated vasculitis.21-23 Those promising results led to the current study, which suggests that rituximab plus glucocorticoids provides similar results to cyclophosphamide plus glucocorticoids for induction of remission.
The observed treatment effects were consistent across all measures of clinical efficacy. A higher percentage of rituximab-treated patients reached the primary end point (64% vs. 53%); the difference exceeded the prespecified noninferiority margin by 31%. In addition, in a prespecified subgroup analysis,31 patients who presented with relapsing disease and who received rituximab fared substantially better than did those with relapsing disease who received cyclophosphamide. Among patients with severe renal disease or alveolar hemorrhage, the outcomes were similar with the two treatment regimens.
The likelihood of remission at 6 months is affected by whether glucocorticoids have been tapered and discontinued entirely, as well as by the specific definition of remission.32-35 Several differences in trial design may explain why the remission rates in this trial were lower than those in some other vasculitis trials.10,11,32-35 Particularly important is the fact that in other vasculitis trials, patients have generally been permitted to continue to receive glucocorticoids for 1 year or longer. In addition, some of the patients in other trials who were classified as being in remission had the continuation of one or more minor BVAS items (i.e., a score higher than 0).
We anticipated lower rates of certain adverse events in the rituximab group, but we did not observe major differences between the two groups in overall adverse events. There are several possible reasons for this finding. First, adverse events, by their definition, include both disease and treatment complications, including those related to glucocorticoid use. Second, 6 months may have been too short a period in which to detect some of the cyclophosphamide-associated adverse events (e.g., infertility). Third, rigorous monitoring of all patients in our trial may have reduced the incidence of cyclophosphamide-induced leukopenia, which may occur in clinical practice if blood counts are not checked every 2 weeks.
Our trial had certain limitations. We enrolled only patients with severe ANCA-associated vasculitis who were ANCA-positive. Thus, it is not clear whether the treatment effects extend to patients with limited Wegener's granulomatosis or those who are ANCA-negative.6 Patients with alveolar hemorrhage severe enough to require ventilatory support and those with advanced renal dysfunction (serum creatinine level, >4.0 mg per deciliter [354 μmol per liter]) were excluded. Thus, the comparative efficacy of these two regimens is uncertain in such patients.
Our study focused exclusively on remission induction but did not address the question of retreatment with rituximab. Rituximab was not readministered after the return of peripheral-blood B cells (anticipated by 9 to 12 months). Longer follow-up in the present trial is important to understand the benefits and risks of rituximab therapy for ANCA-associated vasculitis. Evaluations of patients followed for a minimum of 18 months will explore issues such as the need for retreatment, particularly in the context of peripheral B-cell reconstitution. The finding that loss of proteinase 3−ANCA production occurred more frequently with rituximab therapy than with cyclophosphamide therapy suggests that these two treatment strategies modulate proteinase 3−producing cells differently. Since the ANCA response was not associated with the primary end point, it is possible that the clinical efficacies of both rituximab and cyclophosphamide are due to mechanisms beyond autoantibody suppression.
In conclusion, our data suggest that treatment with rituximab and glucocorticoids is not inferior to the standard regimen in patients with severe ANCA-associated vasculitis of recent onset. Moreover, the regimen may be superior to the standard regimen of cyclophosphamide and glucocorticoids for remission induction in severe relapsing ANCA-associated vasculitis.
Supported by a grant from the National Institute of Allergy and Infectious Diseases to the Immune Tolerance Network (N01-AI-15416; protocol no. ITN021AI). Genentech and Biogen provided the study medications and partial funding. At the Mayo Clinic and Foundation, the trial was supported by a Clinical and Translational Science Award from the National Center for Research Resources (NCRR) (RR024150-01); at Johns Hopkins University, by grants from the NCRR (RR025005) and career development awards (K24 AR049185, to Dr. Stone, and K23 AR052820, to Dr. Seo); and at Boston University, by a Clinical and Translational Science Award (RR 025771), grants from the National Institutes of Health (M01 RR00533) and a career development award (K24 AR02224, to Dr. Merkel), and an Arthritis Foundation Investigator Award (to Dr. Monach). Enzyme-linked immunosorbent assay kits for antineutrophil cytoplasmic antibody were provided by Euroimmun (Lübeck, Germany).
The views expressed in this article are those of the authors and do not necessarily reflect those of the Food and Drug Administration.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Source Information
From Massachusetts General Hospital (J.H.S.) and Boston University Medical Center (P.A. Merkel, E.Y.K., P.A. Monach) — both in Boston; Hospital for Special Surgery, New York (R.S.); Johns Hopkins University, Baltimore (P.S., L.P.S., D.G.); Cleveland Clinic Foundation, Cleveland (C.A.L., G.S.H.); University of Groningen, Groningen, the Netherlands (C.G.M.K., C.S.); Duke University, Durham, NC (E.W.S.C., N.B.A.); University of Alabama–Birmingham, Birmingham (A.T.); Immune Tolerance Network (N.K.T., V.S.-M., M.M.) and National Institute of Allergy and Infectious Diseases (L.W., L.D.) — both in Bethesda, MD; Food and Drug Administration, Rockville, MD (V.S.-M.); Mayo Clinic and Foundation, Rochester, MN (K.M., F.C.F., K.A.K., T.P., S.R.Y., U.S.); Rho, Raleigh, NC (D.W., D.I.); and Genentech, South San Francisco, CA (P.B.).
Address reprint requests to Dr. Specks at the Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, or at specks.ulrich@mayo.edu.
Members of the Rituximab in ANCA-Associated Vasculitis−Immune Tolerance Network (RAVE-ITN) Research Group are listed in the Appendix.
Appendix
Members of the RAVE-ITN Research Group are as follows: Protocol Cochairs — U. Specks (Mayo Clinic), J.H. Stone (Massachusetts General Hospital); Mayo Clinic — U. Specks, S.R. Ytterberg, F.C. Fervenza, K.A. Keogh, T. Peikert, J.M. Golbin, L. Klein, K. Mieras, C. Beinhorn, S. Fisher, M.L. Clawson, S. Bendel, A.M. Hummel (Mayo Clinic Eisenberg Research Pharmacy); Boston University — P.A. Merkel, E.Y. Kissin, P.A. Monach, M.R. Clark-Cotton, C.A. McAlear, J.L. Pettit, M.B. Sutton, R.L. Widom, G.A. Farina, M.J. DiMarzio, S.P. Johnson, A. Schiller Patel; Johns Hopkins University — P. Seo, J.H. Stone, D. Hellmann, D. Geetha, A. Saleh, P. Wung, L.P. Sejismundo, C. Humphrey, M. Marriott, Y. Goldsborough, A. Pinachos, K. Gauss, L. King; Cleveland Clinic Foundation — C.A. Langford, G.S. Hoffman, R.A. Hajj-Ali, J.J. Carey, E.S. Molloy, C.L. Koening, D. Bork, T.M. Clark, K.A. Tuthill, T. Markle, J. Petrich; Hospital for Special Surgery — R. Spiera, D.R. Alpert, S.J. DiMartino, J.K. Gordon, N.K. Moskowitz, K.A. Kirou, J. Samuels, S.A. Kloiber, E. Julevic, M. O'Donohue, A. Patel; University of Groningen — C.G.M. Kallenberg, C. Stegeman, P. Rasker, K. Mulder, P. Limburg, J. Kosterink; Duke University — E.W. St. Clair, N.B. Allen, E. Scarlett, M. Tochacek; University of Alabama–Birmingham — A. Turkiewicz, B. Fessler, W. Chatham, A. Turner; Coordinating Centers: Rho — D. Ikle, D. Weitzenkamp, W. Wu, T. D'Lugin, C. Jacob; National Institute of Allergy and Infectious Diseases — L. Webber, L. Ding, S. Adah; Immune Tolerance Network — N.K. Tchao, M. Mueller, K. Bourcier, A. Asare, V. Seyfert-Margolis, P. Tosta, N.B. Skeeter, C.L. Anderson, A.N. Archampong.
- References
References
1
Jennette JC ,Falk RJ ,Andrassy K , et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192
CrossRef | Web of Science | Medline2
Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120(7):643.e9-643.14.
3
Hoffman GS ,Kerr GS ,Leavitt RY , et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498
Web of Science | Medline4
Guillevin L ,Durand-Gasselin B ,Cevallos R , et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-430
CrossRef | Web of Science | Medline5
Reinhold-Keller E ,Beuge N ,Latza U , et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-1032
CrossRef | Web of Science | Medline6
Stone JH . Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2003;48:2299-2309
CrossRef | Web of Science | Medline7
Novack SN ,Pearson CM . Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-942
Full Text | Web of Science | Medline8
Fauci AS ,Wolff SM . Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973;52:535-561
CrossRef | Web of Science | Medline9
Walton EW . Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958;2:265-270
CrossRef | Web of Science | Medline10
Jayne D ,Rasmussen N ,Andrassy K , et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44
Full Text | Web of Science | Medline11
The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Full Text | Web of Science | Medline12
Seo P ,Min YI ,Holbrook JT , et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-2178
CrossRef | Web of Science | Medline13
Stone JH ,Holbrook JT ,Marriott MA , et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-1618
CrossRef | Web of Science | Medline14
Pagnoux C ,Hogan SL ,Chin H , et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-2918
CrossRef | Web of Science | Medline15
Martin F ,Chan AC . Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 2004;20:517-527
CrossRef | Web of Science | Medline16
Popa ER ,Stegeman CA ,Bos NA ,Kallenberg CG ,Tervaert JW . Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999;103:885-894
CrossRef | Web of Science | Medline17
Stevenson HC ,Fauci AS . Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980;39:391-397
Web of Science | Medline18
Cupps TR ,Edgar LC ,Fauci AS . Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982;128:2453-2457
Web of Science | Medline19
Zhu LP ,Cupps TR ,Whalen G ,Fauci AS . Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987;79:1082-1090
CrossRef | Web of Science | Medline20
Johnson P ,Glennie M . The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:3-8
CrossRef | Web of Science | Medline21
Specks U ,Fervenza FC ,McDonald TJ ,Hogan MC . Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-2840
CrossRef | Web of Science | Medline22
Keogh KA ,Wylam ME ,Stone JH ,Specks U . Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-268
CrossRef | Web of Science | Medline23
Keogh KA ,Ytterberg SR ,Fervenza FC ,Carlson KA ,Schroeder DR ,Specks U . Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187
CrossRef | Web of Science | Medline24
Jones RB ,Tervaert JWC ,Hauser T , et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220
Full Text | Web of Science | Medline25
Stone JH ,Hoffman GS ,Merkel PA , et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44:912-920
CrossRef | Web of Science | Medline26
Exley AR ,Bacon PA ,Luqmani RA , et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-380
CrossRef | Web of Science | Medline27
Ware JE Jr ,Gandek B . Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-912
CrossRef | Web of Science | Medline28
Damoiseaux JG ,Slot MC ,Vaessen M ,Stegeman CA ,Van Paases P ,Tervaert JW . Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J Clin Immunol 2005;25:202-208
CrossRef | Web of Science | Medline29
National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). (Accessed April 29, 2010, at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.)
30
Fauci AS ,Haynes BF ,Katz P . Assessing treatments with cyclophosphamide (in comment). Ann Intern Med 1983;98:1026-1027
Web of Science31
Wang R ,Lagakos SW ,Ware JH ,Hunter DJ ,Drazen JM . Statistics in medicine -- reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194
Full Text | Web of Science | Medline32
Goek ON ,Stone JH . Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 2005;17:257-264
CrossRef | Web of Science | Medline33
Pagnoux C ,Mahr A ,Hamidou MA , et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-2803
Full Text | Web of Science | Medline34
De Groot K ,Rasmussen N ,Bacon PA , et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-2469
CrossRef | Web of Science | Medline35
De Groot K ,Harper L ,Jayne DR , et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-680
Web of Science | Medline
- Citing Articles (94)
Citing Articles
1
Souleymane Brah, Laurent Chiche, Raphaelle Fanciullino, Charléric Bornet, Julien Mancini, Nicolas Schleinitz, Rodolphe Jean, Gilles Kaplanski, Jean-Robert Harlé, Jean-Marc Durand. (2012) Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Annals of Hematology 91:2, 279-285
CrossRef2
Vinayak Ramanath, Ravi Nistala, Kunal Chaudhary. (2012) Update on the role of rituximab in kidney diseases and transplant. Expert Opinion on Biological Therapy 12:2, 223-233
CrossRef3
Marinka Twilt, Susanne Benseler, David Cabral. (2012) Granulomatosis with Polyangiitis in Childhood. Current Rheumatology Reports
CrossRef4
Carol A. Langford. (2012) Update on the Treatment of Granulomatosis with Polyangiitis (Wegener’s). Current Treatment Options in Cardiovascular Medicine
CrossRef5
D. Martorana, F. Maritati, G. Malerba, F. Bonatti, F. Alberici, E. Oliva, P. Sebastio, L. Manenti, R. Brugnano, M. G. Catanoso, P. Fraticelli, G. Guida, G. Gregorini, S. Possenti, G. Moroni, A. Leoni, L. Pavone, A. Pesci, R. A. Sinico, L. Di Toma, M. D'Amico, B. Tumiati, R. D'Ippolito, C. Buzio, T. M. Neri, A. Vaglio. (2012) PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology
CrossRef6
Courtney L. Kraus, Susan M. Culican. (2012) Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease. International Journal of Rheumatology 2012, 1-6
CrossRef7
Augusto Vaglio, Frank Moosig, Jochen Zwerina. (2012) Churg–Strauss syndrome. Current Opinion in Rheumatology 24:1, 24-30
CrossRef8
B. Terrier, S. Pol, V. Thibault, J.-E. Gottenberg, P. Cacoub. (2012) Prise en charge du risque de réactivation du virus de l’hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne : données de l’enquête REACTI-B et proposition d’un algorithme de prise en charge. La Revue de Médecine Interne 33:1, 4-12
CrossRef9
Rodrigo Cartin-Ceba, Fernando C. Fervenza, Ulrich Specks. (2012) Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Current Opinion in Rheumatology 24:1, 15-23
CrossRef10
Mirjan M. van Timmeren, Peter Heeringa. (2012) Pathogenesis of ANCA-associated vasculitis. Current Opinion in Rheumatology 24:1, 8-14
CrossRef11
Philippe Vanhille, Laurence Vrigneaud, Thomas Quéméneur. (2012) Vascularites rénales associées aux ANCA. La Presse Médicale
CrossRef12
Gloria Geldern, Thomas McPharlin, Kyra Becker. (2011) Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit. Neurotherapeutics
CrossRef13
Nikola Lepse, Wayel H. Abdulahad, Cees G.M. Kallenberg, Peter Heeringa. (2011) Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmunity Reviews 11:2, 77-83
CrossRef14
Megan E. B. Clowse, Susannah C. Copland, Tsung-Cheng Hsieh, Shein-Chung Chow, Gary S. Hoffman, Peter A. Merkel, Robert F. Spiera, John C. Davis, W. Joseph McCune, Steven R. Ytterberg, E. William St.Clair, Nancy B. Allen, Ulrich Specks, John H. Stone, . (2011) Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care & Research 63:12, 1777-1781
CrossRef15
Marco A. Alba, Luis F. Flores-Suárez. (2011) Rituximab en el tratamiento de las vasculitis asociadas a ANCA: ¿el futuro hoy?. Reumatología Clínica 7, 41-46
CrossRef16
M. Couderc, J.-E. Gottenberg, X. Mariette, E. Hachulla, J. Sibilia, O. Fain, A. Hot, M. Dougados, L. Euller-Ziegler, P. Bourgeois, C. Larroche, A. Tournadre, Z. Amoura, B. Mazieres, P. Arlet, M. De Bandt, T. Schaeverbeke, M. Soubrier. (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 50:12, 2283-2289
CrossRef17
Andy Abril. (2011) Churg-Strauss Syndrome: An Update. Current Rheumatology Reports 13:6, 489-495
CrossRef18
Peter C. Grayson, J. Mark Sloan, John L. Niles, Paul A. Monach, Peter A. Merkel. (2011) Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. Seminars in Arthritis and Rheumatism 41:3, 424-433
CrossRef19
Jens Witsch, Werner Stenzel, Thilo Witsch, Johann Braun, George Trendelenburg. (2011) Rituximab in c-ANCA associated vasculitic polyneuropathy complicated by local peritonitis. Journal of Neurology 258:12, 2281-2283
CrossRef20
Paul A. Monach, Gunnar Tomasson, Ulrich Specks, John H. Stone, David Cuthbertson, Jeffrey Krischer, Linna Ding, Fernando C. Fervenza, Barri J. Fessler, Gary S. Hoffman, David Ikle, Cees G. M. Kallenberg, Carol A. Langford, Mark Mueller, Philip Seo, E. William St.Clair, Robert Spiera, Nadia Tchao, Steven R. Ytterberg, Yi-Zhong Gu, Ronald D. Snyder, Peter A. Merkel. (2011) Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 63:12, 3988-3997
CrossRef21
Lavnish Joshi, Sue L. Lightman, Alan D. Salama, Amy Lee Shirodkar, Charles D. Pusey, Simon R.J. Taylor. (2011) Rituximab in Refractory Ophthalmic Wegener's Granulomatosis. Ophthalmology 118:12, 2498-2503
CrossRef22
Mariele Gatto, Luca Iaccarino, Mariagrazia Canova, Margherita Zen, Linda Nalotto, Roberta Ramonda, Leonardo Punzi, Andrea Doria. (2011) Pregnancy and vasculitis: A systematic review of the literature. Autoimmunity Reviews
CrossRef23
Wataru Fujii, Masataka Kohno, Hidetaka Ishino, Amane Nakabayashi, Kazuki Fujioka, Takashi Kida, Hidetake Nagahara, Ken Murakami, Kaoru Nakamura, Takahiro Seno, Aihiro Yamamoto, Yutaka Kawahito. (2011) The rapid efficacy of abatacept in a patient with rheumatoid vasculitis. Modern Rheumatology
CrossRef24
M Wendt, I Gunnarsson, J Bratt, A Bruchfeld. (2011) Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scandinavian Journal of Rheumatology1-4
CrossRef25
R. Neal Smith, Robert B. Colvin. (2011) Chronic alloantibody mediated rejection. Seminars in Immunology
CrossRef26
Evans R. Fernández Pérez, Amy L. Olson, Stephen K. Frankel. (2011) Eosinophilic Lung Diseases. Medical Clinics of North America 95:6, 1163-1187
CrossRef27
José A. Gómez-Puerta, Luis F. Quintana, John H. Stone, Manuel Ramos-Casals, Xavier Bosch. (2011) B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmunity Reviews
CrossRef28
Jean Schmidt, Jose S. Pulido, Eric L. Matteson. (2011) Ocular manifestations of systemic disease. Current Opinion in Ophthalmology 22:6, 489-495
CrossRef29
Sana S Siddique, Rajiv Shah, Ana M Suelves, Charles Stephen Foster. (2011) Road to remission: a comprehensive review of therapy in uveitis. Expert Opinion on Investigational Drugs 20:11, 1497-1515
CrossRef30
Chethana Dharmapalaiah, Richard A. Watts. (2011) The role of biologics in treatment of ANCA-associated vasculitis. Modern Rheumatology
CrossRef31
Cees G. M. Kallenberg. (2011) Pathogenesis of ANCA-Associated Vasculitis, an Update. Clinical Reviews in Allergy & Immunology 41:2, 224-231
CrossRef32
J. W. Cohen Tervaert. (2011) Rituximab in ANCA-associated vasculitis: a revolution?. Nephrology Dialysis Transplantation 26:10, 3077-3079
CrossRef33
Uri Arad, Alexandra Balbir-Gurman, Keren Doenyas-Barak, Mirit Amit-Vazina, Dan Caspi, Ori Elkayam. (2011) Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis. Seminars in Arthritis and Rheumatism 41:2, 223-229
CrossRef34
L. Guillevin, A. Mahr. (2011) Rituximab et traitement des vascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles (ANCA). La Revue de Médecine Interne 32:10, 591-593
CrossRef35
N. Mansfield, S. Hamour, A.-M. Habib, R. Tarzi, J. Levy, M. Griffith, T. Cairns, H. T. Cook, C. D. Pusey, A. D. Salama. (2011) Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrology Dialysis Transplantation 26:10, 3280-3286
CrossRef36
Petra M Meiners, Arjan Vissink, Cees GM Kallenberg, Frans GM Kroese, Hendrika Bootsma. (2011) Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opinion on Biological Therapy 11:10, 1381-1394
CrossRef37
Mariagrazia Catanoso, Nicolò Pipitone, Luca Magnani, Luigi Boiardi, Carlo Salvarani. (2011) New indications for biological therapies. Internal and Emergency Medicine 6:S1, 1-9
CrossRef38
Colm McCabe, Quentin Jones, Aikaterini Nikolopoulou, Chris Wathen, Raashid Luqmani. (2011) Pulmonary-renal syndromes: An update for respiratory physicians. Respiratory Medicine 105:10, 1413-1421
CrossRef39
Edward M. Vital, Shouvik Dass, Maya H. Buch, Karen Henshaw, Colin T. Pease, Michael F. Martin, Frederique Ponchel, Andrew C. Rawstron, Paul Emery. (2011) B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis & Rheumatism 63:10, 3038-3047
CrossRef40
Hazlita Isa, Susan Lightman, Charles D Pusey, Simon RJ Taylor. (2011) Ocular manifestations of Wegener’s granulomatosis. Expert Review of Ophthalmology 6:5, 541-555
CrossRef41
K. Owczarczyk, P. Lal, A. R. Abbas, K. Wolslegel, C. T. J. Holweg, W. Dummer, A. Kelman, P. Brunetta, N. Lewin-Koh, M. Sorani, D. Leong, P. Fielder, D. Yocum, C. Ho, W. Ortmann, M. J. Townsend, T. W. Behrens. (2011) A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis. Science Translational Medicine 3:101, 101ra92-101ra92
CrossRef42
Frances Rees, Ramin Yazdani, Peter Lanyon. (2011) Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clinical Rheumatology 30:9, 1241-1245
CrossRef43
Yvette Marie Santiago, Aaron Fay. (2011) Wegener’s Granulomatosis of the Orbit: A Review of Clinical Features and Updates in Diagnosis and Treatment. Seminars in Ophthalmology 26:4-5, 349-355
CrossRef44
Abraham Rutgers, Cees G.M. Kallenberg. (2011) Refractory vasculitis. Autoimmunity Reviews 10:11, 702-706
CrossRef45
Achim Rothe, Andrea Rubbert. (2011) Recombinant proteins in rheumatology – recent advances. New Biotechnology 28:5, 502-510
CrossRef46
R. Cartin-Ceba, K. A. Keogh, U. Specks, S. Sethi, F. C. Fervenza. (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrology Dialysis Transplantation 26:9, 2865-2871
CrossRef47
Julia U. Holle, Wolfgang L. Gross. (2011) Vasculitis syndromes: Rituximab in AAV: when and how to use it. Nature Reviews Rheumatology
CrossRef48
Ediz Dalkilic, Nihan Alkis, Sevil Kamali. (2011) Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Modern Rheumatology
CrossRef49
David S. Pisetsky, Amrie C. Grammer, Tony C. Ning, Peter E. Lipsky. (2011) Are autoantibodies the targets of B-cell-directed therapy?. Nature Reviews Rheumatology 7:9, 551-556
CrossRef50
Lisa WiIlcocks, Rachel Jones, David Jayne. (2011) Lupus nephropathy and vasculitis. Medicine 39:8, 486-491
CrossRef51
E. Reinhold-Keller, F. Moosig. (2011) Entwicklung von Morbidität und Mortalität bei ANCA-assoziierten Vaskulitiden. Zeitschrift für Rheumatologie 70:6, 486-492
CrossRef52
Charles F Henderson, Philip Seo. (2011) Biologic agents in systemic vasculitis. International Journal of Clinical Rheumatology 6:4, 453-462
CrossRef53
L. Guillevin, A. Mahr. (2011) New horizons for treatment of ANCA-associated vasculitides. Rheumatology
CrossRef54
Bouchra El M’Kaddem, Philippe Clapuyt, Jean-Jacques de Bruycker, Bernard Lauwerys, Christian Raftopoulos, Catherine Godfraind, Marie-Cécile Nassogne. (2011) Primary cerebral arteritis in a young girl: An unusual cause of acute recurrent neurological deterioration. European Journal of Paediatric Neurology
CrossRef55
E. Ntatsaki, J. Mooney, R. A. Watts. (2011) ANCA vasculitis: time for a change in treatment paradigm? Not yet. Rheumatology 50:6, 1019-1024
CrossRef56
Andrew I Shulman, Marilynn Punaro. (2011) Critical care of the pediatric patient with rheumatic disease. Current Opinion in Pediatrics 23:3, 263-268
CrossRef57
J.U. Holle, F. Moosig, W.L. Gross. (2011) Therapiestrategien bei Vaskulitiden. Der Internist 52:6, 671-681
CrossRef58
M.-J. C. J. Guerry, P. Brogan, I. N. Bruce, D. P. D'Cruz, L. Harper, R. Luqmani, C. D. Pusey, A. D. Salama, D. G. I. Scott, C. O. S. Savage, R. A. Watts, D. R. W. Jayne. (2011) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology
CrossRef59
Jeffrey A. Bluestone. (2011) Mechanisms of tolerance. Immunological Reviews 241:1, 5-19
CrossRef60
Ruth M. Tarzi, Charles D. Pusey. (2011) Vasculitis: Risks and rewards of treating elderly patients with vasculitis. Nature Reviews Nephrology 7:5, 253-255
CrossRef61
J. Niles. (2011) Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clinical & Experimental Immunology 164, 27-30
CrossRef62
Gerald T. Nepom, E. William St. Clair, Laurence A. Turka. (2011) Challenges in the pursuit of immune tolerance. Immunological Reviews 241:1, 49-62
CrossRef63
C. A. Langford. (2011) Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clinical & Experimental Immunology 164, 31-34
CrossRef64
M. Haubitz. (2011) Vaskulitiden. Der Nephrologe 6:3, 249-257
CrossRef65
H. Tadema, W. H. Abdulahad, N. Lepse, C. A. Stegeman, C. G. M. Kallenberg, P. Heeringa. (2011) Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology 50:4, 689-696
CrossRef66
Michael Walsh, Fausta Catapano, Wladimir Szpirt, Kristian Thorlund, Annette Bruchfeld, Loic Guillevin, Marion Haubitz, Peter A. Merkel, Chen Au Peh, Charles Pusey, David Jayne. (2011) Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. American Journal of Kidney Diseases 57:4, 566-574
CrossRef67
Ronald F. van Vollenhoven. (2011) Unresolved issues in biologic therapy for rheumatoid arthritis. Nature Reviews Rheumatology 7:4, 205-215
CrossRef68
Sally M Hamour, Alan D Salama. (2011) ANCA comes of age—but with caveats. Kidney International 79:7, 699-701
CrossRef69
Benjamin Wilde, Pieter van Paassen, Oliver Witzke, Jan Willem Cohen Tervaert. (2011) New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney International 79:6, 599-612
CrossRef70
Sanjeev Baweja, Kate Wiggins, Darren Lee, Susan Blair, Margaret Fraenkel, Lawrence P. McMahon. (2011) Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. Journal of Artificial Organs 14:1, 9-22
CrossRef71
V. Cottin, Ch. Khouatra, L. Kiakouama, J.-F. Cordier. (2011) Vascularites pulmonaires. Revue des Maladies Respiratoires Actualités 3, S67-S75
CrossRef72
Cándido Díaz-Lagares, Roberto Pérez-Alvarez, Francisco J García-Hernández, María M Ayala-Gutiérrez, José Callejas, Agustín Martínez-Berriotxoa, Javier Rascón, Luis Caminal-Montero, Albert Selva-O'Callaghan, Joaquim Oristrell, Carmen Hidalgo, Ricardo Gómez-de-la-Torre, Luis Sáez, Jesús Canora-Lebrato, María-Teresa Camps, Norberto Ortego-Centeno, María-Jesús Castillo-Palma, Manuel Ramos-Casals, . (2011) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research & Therapy 13:4, R112
CrossRef73
Usama Elewa, Ana Maria Sandri, W. Ray Kim, Fernando C. Fervenza. (2011) Treatment of Hepatitis B Virus-Associated Nephropathy. Nephron Clinical Practice 119:1, c41-c49
CrossRef74
Alina Casian, David Jayne. (2011) Plasma exchange in the treatment of Wegenerʼs granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome and renal limited vasculitis. Current Opinion in Rheumatology 23:1, 12-17
CrossRef75
Mateo Porres-Aguilar, Juan B. Figueroa-Casas, Mateo Porres-Muñoz, C. Gregory Elliott. (2011) A 38-Year-Old Pregnant Woman with Hemoptysis and Acute Renal Failure. Respiration 82:1, 60-64
CrossRef76
Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, Mathias Grunke, Joerg Henes, Ina Kötter, Judith Haas, Leonore Unger, Svjetlana Lovric, Marion Haubitz, Rebecca Fischer-Betz, Gamal Chehab, Andrea Rubbert-Roth, Christof Specker, Jutta Weinerth, Julia Holle, Ulf Müller-Ladner, Ramona König, Christoph Fiehn, Philip Burgwinkel, Klemens Budde, Helmut Sörensen, Michael Meurer, Martin Aringer, Bernd Kieseier, Cornelia Erfurt-Berge, Michael Sticherling, Roland Veelken, Ulf Ziemann, Frank Strutz, Praxis von Wussow, Florian MP Meier, Nico Hunzelmann, Enno Schmidt, Raoul Bergner, Andreas Schwarting, Rüdiger Eming, Michael Hertl, Rudolf Stadler, Michael Schwarz-Eywill, Siegfried Wassenberg, Martin Fleck, Claudia Metzler, Uwe Zettl, Jens Westphal, Stefan Heitmann, Anna L Herzog, Heinz Wiendl, Waltraud Jakob, Enno Schmidt, Klaus Freivogel, Thomas Dörner, . (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research & Therapy 13:3, R75
CrossRef77
Dimitrios Daoussis, Stamatis-Nick C. Liossis, Georgios Yiannopoulos, Andrew P. Andonopoulos. (2011) B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence. International Journal of Rheumatology 2011, 1-7
CrossRef78
B. Tönshoff. (2011) Mycophenolatmofetil vs. Azathioprin bei ANCA-assoziierten Vaskulitiden. Der Nephrologe 6:1, 62-63
CrossRef79
Dario Roccatello, Savino Sciascia, Daniela Rossi, Mirella Alpa, Carla Naretto, Alessandra Russo, Elisa Menegatti, Simone Baldovino. (2011) Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. American Journal of Nephrology 34:2, 175-180
CrossRef80
Julia U Holle, Frank Moosig, Klaus Dalhoff, Wolfgang L Gross. (2011) Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Research & Therapy 13:3, 224
CrossRef81
Ulf Schönermarck, Kirsten de Groot. (2011) Vasculitis: Rituximab: effective in ANCA-associated vasculitis?. Nature Reviews Nephrology 7:1, 6-8
CrossRef82
C. Francès, N. Kluger, M.-S. Doutre. (2011) Vasculitis cutáneas y cutaneosistémicas. EMC - Dermatología 45:4, 1-20
CrossRef83
Gunnar Tomasson, Maarten Boers, Michael Walsh, Michael LaValley, David Cuthbertson, Simon Carette, John C. Davis, Gary S. Hoffman, Nader A. Khalidi, Carol A. Langford, Carol A. McAlear, W. Joseph McCune, Paul A. Monach, Philip Seo, Ulrich Specks, Robert Spiera, E. William St. Clair, John H. Stone, Steven R. Ytterberg, Peter A. Merkel. (2011) Assessment of health related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care & Researchn/a-n/a
CrossRef84
Liana Fraenkel. (2010) The downsides of a major medical advance. Arthritis Care & Research 62:12, 1679-1681
CrossRef85
Cees G. M. Kallenberg. (2010) Pathophysiology of ANCA-Associated Small Vessel Vasculitis. Current Rheumatology Reports 12:6, 399-405
CrossRef86
(2010) Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine 363:21, 2072-2074
Full Text87
D. Stoffler, F.J. Meyer, V. Schwenger. (2010) Das pulmorenale Syndrom auf der Intensivstation. Der Pneumologe 7:6, 434-440
CrossRef88
Jeffrey A. Bluestone, Hugh Auchincloss, Gerald T. Nepom, Daniel Rotrosen, E. William St. Clair, Laurence A. Turka. (2010) The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology 10:11, 797-803
CrossRef89
Min Chen, Cees G. M. Kallenberg. (2010) ANCA-associated vasculitides—advances in pathogenesis and treatment. Nature Reviews Rheumatology 6:11, 653-664
CrossRef90
Shreeya Nanda. (2010) Therapy: Rituximab has similar short-term safety and efficacy to cyclophosphamide in ANCA-associated vasculitis. Nature Reviews Rheumatology 6:10, 556-556
CrossRef91
J.U. Holle, T. Bley, W.L. Gross. (2010) Klassifikation und leitliniengerechte Empfehlungen zur Diagnose und Therapie von Vaskulitiden. Der Radiologe 50:10, 846-854
CrossRef92
Ahmad B. Tarabishy, Mark Schulte, George N. Papaliodis, Gary S. Hoffman. (2010) Wegener's Granulomatosis: Clinical Manifestations, Differential Diagnosis, and Management of Ocular and Systemic Disease. Survey of Ophthalmology 55:5, 429-444
CrossRef93
Jones, Rachel B., Cohen Tervaert, Jan Willem, Hauser, Thomas, Luqmani, Raashid, Morgan, Matthew D., Peh, Chen Au, Savage, Caroline O., Segelmark, Mårten, Tesar, Vladimir, van Paassen, Pieter, Walsh, Dorothy, Walsh, Michael, Westman, Kerstin, Jayne, David R.W., . (2010) Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine 363:3, 211-220
Full Text94
Falk, Ronald J., Jennette, J. Charles, . (2010) Rituximab in ANCA-Associated Disease. New England Journal of Medicine 363:3, 285-286
Full Text
- Letters
